Open AccessA long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges
Author(s) -
Martina Kovářová,
Meghan R. Swanson,
Rosa I. Sánchez,
Caroline Baker,
Justin Steve,
Rae Ann Spagnuolo,
Bonnie Howell,
Daria J. Hazuda,
Víctor Moreno
Publication year - 2016
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/50yt-m563
Subject(s) - raltegravir , humanized mouse , human immunodeficiency virus (hiv) , integrase , integrase inhibitor , pharmacology , virology , medicine , viral load , antiretroviral therapy , immunology , immune system